Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United St…
$37.34-1.81%
报价 2026-11-06
市值
$1.7B
EV
$1.57B
PE (TTM)
38.3x
预期 PE (FY2026)
15.0x
52 周区间距高点 -27.3%
$32.23$51.39
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 2.47 → 2.01（0.8x） | 18.6 |
| FY+32028-12 | 1.0x | 2.47 → 2.26（0.9x） | 16.5 |
毛利率 45% · TTM 收入 $1244M · 基数 EPS 2.47（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| OMCLOmnicell, Inc. | $1.7B | -1.8% | +3.8% | 44.8% | 38.3x | 10.5x | 11.7x | |
| TXG10x Genomics, Inc. | $7.13B | +2.1% | -2.5% | 74.5% | – | 204.2x | 66.8x | |
| PGNYProgyny, Inc. | $2.67B | +1.4% | +7.6% | 24.5% | 30.3x | 18.4x | 12.2x | |
| UFPTUFP Technologies, Inc. | $2.35B | +1.2% | +9.1% | 29.3% | 33.3x | 22.8x | 41.6x | |
| SDGRSchrödinger, Inc. | $2.23B | +3.6% | -4.3% | 59.3% | – | – | – | |
| ASTHAstrana Health, Inc. | $1.71B | -11.6% | +26.0% | 10.7% | 45.8x | 12.9x | 11.9x | |
| TDOCTeladoc Health, Inc. | $1.6B | -6.8% | -4.1% | 68.6% | – | 7.5x | 6.9x | |
| GDRXGoodRx Holdings, Inc. | $1.2B | +0.6% | +0.6% | 89.5% | 66.7x | 8.4x | 8.2x | |
| OMDAOmada Health | $923.8M | -20.4% | +33.4% | 75.9% | 169.6x | 40.3x | 32.8x | 高增长 |
| 同行中位数 | – | – | +4.1% | 63.9% | 45.8x | 18.4x | 12.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $307.9M | $312.2M | $309.9M | $314M | $310.6M | $290.6M | $269.7M | $306.9M |
| Gross Margin | 44.8% | 49% | 45.3% | 41.5% | 43.3% | 43.9% | 41.1% | 46.6% |
| Operating Margin | 4.9% | 10.4% | 5.4% | 0.5% | 2.7% | 2.8% | -4.3% | 4.5% |
| Net Income | $11M | $24.3M | $11.4M | $-2M | $5.5M | $5.6M | $-7M | $15.8M |
| Diluted EPS | 0.24 | 0.52 | 0.25 | -0.05 | 0.12 | 0.12 | -0.15 | 0.34 |
| Operating Cash Flow | $33.1M | $69.5M | $54.5M | $30.4M | $28.3M | $42.8M | $25.9M | $56.3M |